옵션 체인은 다양한 행사가격과 만기일에 대한 Tonix Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Tonix Pharmaceuticals에 대한 시장 심리를 평가합니다..

Tonix Pharmaceuticals (NASDAQ:TNXP) 주식, 옵션 체인

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.37) by 15.73 percent. This is a 99.51 percent increase over losses of $(576.00) per share from the same period last year. The company reported quarterly sales of $2.43 million which missed the analyst consensus estimate of $2.55 million by 4.75 percent. This is a 2.14 percent decrease over sales of $2.48 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

TNXP

Tonix Pharmaceuticals Q1 EPS $(2.84) Beats $(3.37) Estimate, Sales $2.43M Miss $2.55M Estimate

Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells
TNX-1700 is in preclinical development for gastric and colorectal cancers

Biotech

Events

General

Tonix Pharmaceuticals Presented Preclinical Data On Gastric Cancer Models At AACR 2025 Annual Meeting

Tonix Pharmaceuticals Discontinued Enrollment And Terminated Phase 2 Catalyst Study Of Its TNX-1300 Product; The Company Is Evaluating New Study Designs And New Endpoints For Further Development Of TNX-1300

Agreement includes the use of Tonix's TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana's genetically engineered pig organs in xenotransplantation.
 &nbsp;

Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) With Makana's Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Health Care

Tonix Pharmaceuticals Presented Data And Analyses Of TNX-102 SL Treatment Effects On Fibromyalgia At The American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 38.44% since its last report. The company recently reported that it has 878 thousand shares sold short, which is 13.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743789771_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 11.36%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Tonix Pharmaceuticals's Recent Short Interest

Tonix Pharmaceuticals Launches TONIX ONE: A Comprehensive Digital Platform For Migraine Management In Partnership With UpScript, ProModRx, Blink Health, And Leading Symptom-Tracking App

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) are trading lower by 6.8% to $26.83 during Thursday&#8217;s session, potentially pulling back on profit-taking, after surging around 60% this week <a href="https://www.benzinga.com/news/25/03/44457827/why-tonix-pharmaceuticals-tnxp-stock-is-rising">following a regulatory update</a> on its experimental fibromyalgia treatment, TNX-102 SL.
What To Know: Tonix announced on Tuesday that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, removing a potential roadblock in the approval process. This decision brings the company one step closer to a potential Q4 2025 launch, pending final FDA approval.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44514663/whats-going-on-with-cava-group-stock-thursday">What&#8217;s Going On With Cava Group Stock Thursday?</a> CEO Seth Lederman emphasized the drug&#8217;s potential to introduce a new class of fibromyalgia treatments, offering hope to millions of patients struggling with this chronic pain disorder.
TNX-102 SL is a sublingual formulation of cyclobenzaprine HCl, designed to improve symptom management in fibromyalgia patients. The drug was granted Fast Track designation in 2024, expediting its regulatory review.
Tonix says the company remains optimistic about the drug's potential to provide a new, effective treatment option for patients seeking relief.
Read Also: <a href="https://www.benzinga.com/markets/25/03/44509733/gm-ford-tesla-and-other-auto-stocks-slide-in-thursday-pre-market-whats-going-on">GM, Ford, Tesla And Other Auto Stocks Slide In Thursday Pre-Market: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Tonix Pharmaceuticals, which is trading at $25.76 as of publishing time, $100 would buy you 3.88 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $1,146.01 and a 52-week low of $6.76.

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Arcutis Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>)</h3>
<ul>
<li>Health Canada, on March 17, approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis. This approval comes after data from phase 3 clinical trials showed that 90% of patients experienced symptom improvement within four weeks and 69% achieved at least a 50% reduction in disease severity. The company's stock gained around 42% over the past month and has a <a href="https://www.benzinga.com/quote/ARQT">52-week high of $17.70</a>.</li>
<li>RSI Value: 71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics gained 1.7% to close at $17.29 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>)</h3>
<ul>
<li>On March 24, Tonix Pharmaceuticals Holding announced that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia. The company's stock gained around 279% over the past month and <a href="https://www.benzinga.com/quote/TNXP">has a 52-week high </a>of $1,145.92.</li>
<li>RSI Value: 77.1</li>
<li>TNXP Price Action: Shares of Tonix Pharmaceuticals gained 32.5% to close at $30.51 on Monday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44457888/top-2-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 2 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>
Photo: Raker via Shutterstock

Pre-Market Outlook

Markets

ARQT

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares moved upwards by 75.6% to $3.02 during Monday's regular session. The market value of their outstanding shares is at $4.2 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock rose 57.28% to $2.38. The company's market cap stands at $14.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 26.24% to $29.07. The company's market cap stands at $187.0 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) shares moved upwards by 23.57% to $3.35. The company's market cap stands at $110.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock rose 23.55% to $7.03. The market value of their outstanding shares is at $350.8 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock moved upwards by 22.81% to $1.22. The market value of their outstanding shares is at $92.4 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares declined by 52.1% to $0.86 during Monday's regular session. The company's market cap stands at $23.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 40.18% to $0.67. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 31.08% to $3.42. The company's market cap stands at $39.3 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) shares declined by 30.96% to $1.26. The company's market cap stands at $21.2 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock declined by 25.81% to $7.14. The market value of their outstanding shares is at $7.3 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock decreased by 24.64% to $10.77. The company's market cap stands at $93.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADTX

CAPS

CRVO

CYRX

KDLY

LXEO

RNAZ

12 Health Care Stocks Moving In Monday's Intraday Session

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher by 25.3% to $28.85 during Monday&#8217;s session after the company announced that the FDA <a href="https://www.benzinga.com/pressreleases/25/03/g44455533/tonix-pharmaceuticals-announces-that-fda-will-not-require-an-advisory-committee-meeting-to-discuss">will not require</a> an Advisory Committee meeting for its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia.
What To Know: CEO Seth Lederman expressed confidence in the drug's potential to introduce a new class of fibromyalgia treatments. The company anticipates a possible launch in Q4 2025, pending FDA approval. 
TNX-102 SL, a sublingual formulation of cyclobenzaprine HCl, previously received Fast Track designation in 2024, expediting its regulatory review.
Tonix says, with over 10 million U.S. adults affected by fibromyalgia, the approval of TNX-102 SL could mark a significant advancement in addressing this chronic pain disorder. Tonix remains optimistic about the drug's potential to meet the unmet needs of fibromyalgia patients.
Read Also: <a href="https://www.benzinga.com/markets/25/03/44455074/oil-rises-as-us-and-russia-begin-talks-in-saudi-arabia-for-ukraine-ceasefire-black-sea-deal">Oil Rises As US And Russia Begin Talks In Saudi Arabia For Ukraine Ceasefire, Black Sea Deal</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Tonix Pharmaceuticals, which is trading at $23.03 as of publishing time, $100 would buy you 4.34 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $1,146.01 and a 52-week low of $6.76.

Why Tonix Pharmaceuticals (TNXP) Stock Is Rising

WIIM

Tonix Pharmaceutical shares are trading higher after the company announced the FDA will not require an advisory committee for Tnx-102 SL.

Tonix Pharmaceuticals Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss The Company's New Drug Applicatio For Tnx-102 Sl For The Management Of Fibromyalgia; If Approved, Tnx-102 Sl (cyclobenzaprine Hcl Sublingual Tablets) Would Be The First New Treatment Option For Fibromyalgia Patients In 15 Years

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 98.1% to $4.12 during Friday's regular session. The company's market cap stands at $47.4 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 60.9% to $1.24. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares increased by 40.09% to $5.8. The market value of their outstanding shares is at $7.6 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 30.36% to $58.67. The market value of their outstanding shares is at $763.4 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock moved upwards by 26.71% to $23.05. The company's market cap stands at $128.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares moved upwards by 21.49% to $14.04. The market value of their outstanding shares is at $115.9 million. As per the press release, Q4 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock fell 62.1% to $0.58 during Friday's regular session. The company's market cap stands at $5.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares decreased by 38.47% to $1.44. The market value of their outstanding shares is at $56.7 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares declined by 31.95% to $0.28. The market value of their outstanding shares is at $2.9 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock declined by 23.4% to $1.67. The market value of their outstanding shares is at $1.2 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares decreased by 16.92% to $37.17. The company's market cap stands at $226.8 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares fell 14.53% to $0.22. The company's market cap stands at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GCTK

GLTO

MNPR

STSS

TCBP

TELA

WINT

12 Health Care Stocks Moving In Friday's Intraday Session

Noble Capital Markets analyst Robert LeBoyer reiterates Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) with a Outperform and maintains $70 price target.

Price Target

Reiteration

Analyst Ratings

Noble Capital Markets Reiterates Outperform on Tonix Pharmaceuticals, Maintains $70 Price Target

<h3>Gainers</h3>
<ul>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock moved upwards by 17.37% to $3.35. The company's market cap stands at $2.2 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock rose 16.98% to $1.86. The market value of their outstanding shares is at $16.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 19.9% to $16.45 during Wednesday's regular session. The company's market cap stands at $91.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 17.91% to $1.88. The market value of their outstanding shares is at $28.5 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock declined by 17.54% to $83.84. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock decreased by 16.84% to $1.68. The company's market cap stands at $8.3 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares decreased by 15.84% to $2.69. The market value of their outstanding shares is at $324.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock fell 14.49% to $17.95. The company's market cap stands at $46.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BDTX

CANF

HURA

INTS

LYEL

OABI

SCNX

VERO

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Tonix Pharmaceuticals Holdings shares are trading lower after the company reported mixed Q4 financial results.

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ABSI/earnings">worse-than-expected fourth-quarter financial results.</a>
Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This is unchanged from the same period last year. The company reported quarterly sales of $665.000 thousand which missed the analyst consensus estimate of $1.778 million.
Absci shares dipped 9.4% to $2.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares dipped 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares fell 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) declined 6.5% to $1.30 in pre-market trading following a 5% fall on Tuesday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) declined 4.3% to $34.53 in pre-market trading after dipping 18% on Tuesday.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) fell 3.8% to $5.63 in pre-market trading.</li>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) fell 3.2% to $31.47 in pre-market trading after gaining 14% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>
Photo: Shutterstock

ABSI

ATGL

RHLD

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/STNE/earnings">earnings and sales results</a>.
StoneCo shares jumped 8% to $10.64 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Leishen Energy Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NASDAQ">LSE</a>) gained 90% to $14.31 in pre-market trading after jumping over 46% on Tuesday. The company recently reported FY24 financial results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) rose 35.4% to $0.1760 in pre-market trading after the company announced positive results from a beagle dog dose range-finding study.</li>
<li>TEN Holdings, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) gained 34% to $0.7839 in pre-market trading. TEN Holdings shares jumped 18% on Tuesday after the company announced a $1 million stock repurchase program.</li>
<li>Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) gained 27% to $2.68 in pre-market after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Bowen Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOWN#NASDAQ">BOWN</a>) gained 24% to $5.43 in pre-market trading after jumping 5% on Tuesday.</li>
<li>CARGO Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) gained 21.1% to $4.60 in pre-market trading after the company suspended CRG-023 &amp; allogeneic platform and initiated 90% workforce reduction.</li>
<li>Hillenbrand, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) gained 17.3% to $29.29 in pre-market trading.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) rose 11.8% to $1.32 in pre-market trading after dipping 23% on Tuesday.</li>
<li>CNS Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) rose 10.4% to $3.92 after surging 16% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>FST Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSX#NASDAQ">KBSX</a>) fell 23.1% to $4.22 in pre-market trading after gaining 310% on Tuesday.</li>
<li>5E Advanced Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>) shares fell 21.2% to $3.08 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) fell 18.5% to $0.2012 in pre-market trading after gaining around 22% on Tuesday. Starbox Group company received staff determination notice from Nasdaq.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) declined 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>OSR Holdings, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) dipped 15.5% to $1.51 in pre-market trading after jumping 34% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares tumbled 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares fell 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares dipped 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell 9.4% to $2.79 in today's pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) fell 6.5% to $1.30 in pre-market trading after declining around 5% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>
Photo: Shutterstock

ATER

BOWN

CNSP

CRGX

FEAM

INTZ

KBSX

OSRH

STBX

STNE

VRPX

XHLD

Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket

Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) reported quarterly losses of $(9.77) per share which beat the analyst consensus estimate of $(291.74) by 96.65 percent. The company reported quarterly sales of $2.600 million which missed the analyst consensus estimate of $3.500 million by 25.71 percent. This is a 31.20 percent decrease over sales of $3.779 million the same period last year.

Tonix Pharmaceuticals Q4 2024 GAAP EPS $(9.77) Beats $(291.74) Estimate, Sales $2.600M Miss $3.500M Estimate

Press Releases

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Management

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Anika Therapeutics

Atossa Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Editas Medicine

EXoZymes

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

Korro Bio

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Puma Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prime Medicine

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Exagen

Y-mAbs Therapeutics

Noble Capital Markets

Alliance Global Partners

Dawson James

Untitled design - 2025-03-31T165341.547

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-03-19 at 8.55.22 PM

BVNKF

As Mpox Cases Spread Around The World, Tonix Pharmaceuticals&#39; Single-Dose Vaccine TNX-801 Has Potential To Slow The Spread

Screenshot 2025-03-12 at 4.47.01 PM

AMGN

BIIB

ELDN

Tonix&#39;s TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target

Untitled design - 2024-12-07T011441.837

Tonix&#39;s TNX 102-SL Could Offer New Hope Of Pain Relief Without Narcotics For Fibromyalgia Sufferers

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Untitled design - 2024-09-04T162950.621

As Research Into Pain Accelerates, A Newly Recognized Type Of Pain Comes To The Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL

Screenshot 2024-08-23 at 3.09.59 AM

Modern Twist To Centuries-Old Smallpox Vaccine Could Be Poised To Combat Deadly Mpox Strain As WHO Declares Global Emergency

Screenshot 2024-08-01 at 5.06.20 PM

FDA Recognizes Fibromyalgia As A &#39;Serious Condition&#39; And Fast-Tracks New Drug Candidate

Comments

Tonix Pharmaceuticals

Tonix Pharmaceuticals (TNXP) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌